Skip to main content
Fig. 4 | Diabetology & Metabolic Syndrome

Fig. 4

From: The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg

Fig. 4

Adapted from Pi-Sunyer et al. [37]

Mean body weight loss and categorical weight loss in the SCALE Obesity and Pre-diabetes study. a The mean body weight for patients in the full-analysis set who completed each scheduled visit, according to presence or absence of prediabetes at screening. I bars indicate standard error, and the separate symbols above the curves represent the 56-week weight change using last-observation-carried-forward (LOCF) imputation. Percentages of weight change in the liraglutide group were 8.0% with LOCF imputation and 9.2% for completers. In the placebo group, the changes were 2.6% with LOCF imputation and 3.5% for completers. The full-analysis set comprised patients who underwent randomization, were exposed to at least one treatment dose, and had at least one assessment after baseline (69 patients were excluded from the full-analysis set: 61 owing to lack of an assessment and 8 owing to no exposure). b The proportions of patients who lost at least 5%, more than 10%, and more than 15% of their baseline body weight. Data shown are the observed means for the full-analysis set (with LOCF). Findings from logistic-regression analysis showed an odds ratio of 4.8 (95% confidence interval [CI], 4.1 to 5.6) for at least 5% weight loss and an odds ratio of 4.3 (95% CI, 3.5 to 5.3) for more than 10% weight loss; the analysis of more than 15% weight loss was performed post hoc (odds ratio, 4.9 [95% CI, 3.5 to 6.7])

Back to article page